The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds
Open accessAbstract
The recently emerged 2019 Novel Coronavirus (SARS‐CoV‐2) and associated COVID‐19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS‐CoV‐2. Along these efforts, the structure of SARS‐CoV‐2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform – Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure‐based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS‐CoV‐2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking.
Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300687e · Cited by 2,412
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Cited by
Computational approaches streamlining drug discovery
Sadybekov, A. V., & Katritch, V. (2023) · Nature · doi:10.1038/s41586-023-05905-z · Cited by 1,279
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Gentile, F., Yaacoub, J. C., Gleave, J., Fernandez, M., Ton, A.-T., Ban, F., Stern, A., & Cherkasov, A. (2022) · Nature Protocols · doi:10.1038/s41596-021-00659-2 · Cited by 397
Self-citationPham, Q.-V., Nguyen, D. C., Huynh-The, T., Hwang, W.-J., & Pathirana, P. N. (2020) · IEEE Access · doi:10.1109/access.2020.3009328 · Cited by 413
“Besides drug repur-posing, many have been devoted to drug discovery [89], [91]– [93] and protein structure prediction [94]–[96] for combating against the COVID-19 pandemic.”
BackgroundIntegrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00832-0 · Cited by 397
Self-citationChinese Public's Attention to the COVID-19 Epidemic on Social Media: Observational Descriptive Study
Zhao, Y., Cheng, S., Yu, X., & Xu, H. (2020) · Journal of Medical Internet Research · doi:10.2196/18825 · Cited by 364
Advances in De Novo Drug Design: From Conventional to Machine Learning Methods
Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., & Melagraki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041676 · Cited by 353
Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery
Muhammed, M. T., & Aki-Yalcin, E. (2024) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220922103109 · Cited by 267
Cheng, Y.-W., Chao, T.-L., Li, C.-L., Chiu, M.-F., Kao, H.-C., Wang, S.-H., Pang, Y.-H., Lin, C.-H., Tsai, Y.-M., Lee, W.-H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108254 · Cited by 257
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
Self-citationA critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206
Self-citationArtificial Intelligence for COVID-19: Rapid Review
(2020) · doi:10.2196/21476 · Cited by 160
Lv, H., Shi, L., Berkenpas, J. W., Dao, F.-Y., Zulfiqar, H., Ding, H., Zhang, Y., Yang, L., & Cao, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab320 · Cited by 107
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
Floresta, G., Zagni, C., Gentile, D., Patamia, V., & Rescifina, A. (2022) · doi:10.20944/preprints202203.0032.v1 · Cited by 67
Metadata
- Authors
- Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A.
- Venue
- Molecular Informatics
- Publisher
- Wiley
- Published
- 2020-03-23
- Volume
- 39
- Issue
- 8
- Pages
- e2000028-e2000028
- ISSN
- 1868-1743 (ISSN-L)
- 1868-1751
- OpenAlex
- W3009970748
- Cited by
- 517
- References
- 53
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.